Evidence map›Paper›PMID 10400811›Full record

ArticleJournal of virology1999

Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees.

S Santra, P N Fultz, N L Letvin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

S SantraDivision of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
P N Fultz
N L Letvin
Harvard University · USUniversity of Alabama at Birmingham · US

Funding

Novel VLP-Based Mucosal and Sytemic HIV VaccinesU19AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2003 to 2009
$15.8M
POLIOVIRUS REPLICONS FOR HIV/SIV VACCINESP01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MORROW, CASEY D · 1998 to 2002
$5.1M
PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE R&DN01AI085343 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LETVIN, NORMAN L · 1998 to 2000
$412k
RECOMBINANT VACCINES DERIVED FROM POLIOVIRUSU01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI COMPANS, RICHARD W · 1989 to 1997
–
NIAID NIH HHS AI-28147NIAID NIH HHS AI-85343NIAID NIH HHS P01 AI028147NIAID NIH HHS U01 AI028147NIAID NIH HHS U19 AI028147
6 · The paper itself

Abstract

Chimpanzees have been important in studies of human immunodeficiency virus type 1 (HIV-1) pathogenesis and in evaluation of HIV-1 candidate vaccines. However, little information is available about HIV-1-specific cytotoxic T lymphocytes (CTL) in these animals. In the present study, in vitro stimulation of peripheral blood mononuclear cells (PBMC) from infected chimpanzees with HIV-1 Gag peptides was shown to be a sensitive, reproducible method of expanding HIV-1-specific CD8(+) effector CTL. Of interest, PBMC from two chimpanzees had CTL activity against Gag epitopes also recognized by major histocompatibility complex class I-restricted CTL from HIV-1-infected humans. The use of peptide stimulation will help to clarify the role of CTL in vaccine-mediated protection and HIV-1 disease progression in this important animal model.

Indexed as

AnimalsDisease Models, AnimalGene Products, gagHIV-1HIV InfectionsHumansPan troglodytesT-Lymphocytes, CytotoxicGene Products, gag

Identifiers

PMID10400811
PMCPMC112798
OpenAlexW2096182342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.